Global alert and response network for hepatitis C virus-derived heart diseases: A call to action

CVD Prevention and Control

Volumn 4, Issue 2, 2009, Pages 109-118

  Matsumori, Akira ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiomyopathy; Heart failure; Hepatitis C; Myocarditis; Virus

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; INTERFERON;

ARTICLE; CONGESTIVE CARDIOMYOPATHY; DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; GENETIC SUSCEPTIBILITY; HEALTH PROGRAM; HEART DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; LIVER CELL CARCINOMA; MYOCARDITIS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SUDDEN DEATH; VASCULAR DISEASE; VIRUS GENOME;

EID: 62649171630     PISSN: 18754570     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvdpc.2009.02.002     Document Type: Article

References (40)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC, Jr., Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
2. Gheorghiade M., and Bonow R. Heart failure as a consequence of arteriosclerotic coronary artery disease. In: Mann D. (Ed). Heart failure (2004), Saunders, Philadelphia, USA 351-362 [chapter 22]
3. The EPOCH Study Group, Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J 2002;66:149-57.
4. Hori M., Sasayama S., Kitabatake A., Toyo-oka T., Handa S., Yokoyama M., Matsuzaki M., Takeshita A., Origasa H., Matsui K., and Hosoda S. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147 (2004) 324-330
5. Matsumori A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 5 (2003) 669-677
6. Nishigaki K. Indication of recipients for cardiac transplant. Today's Transplant 18 (2005) 294-301
7. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., Olsen E., Thiene G., Goodwin J., Gyarfas I., Martin I., and Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93 (1996) 841-842
8. Maron B.J., Towbin J.A., Thiene G., Antzelevitch C., Corrado D., Arnett D., Moss A.J., Seidman C.E., and Young J.B. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113 (2006) 1807-1816
9. Elliott P., Andersson B., Arbustini E., Bilinska Z., Cecchi F., Charron P., Dubourg O., Kuhl U., Maisch B., McKenna W.J., Monserrat L., Pankuweit S., Rapezzi C., Seferovic P., Tavazzi L., and Keren A. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 (2008) 270-276
10. Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res 96 (2005) 144-147
11. Matsumori A., Matoba Y., Nishio R., Shioi T., Ono K., and Sasayama S. Detection of hepatitis C virus RNA from the heart of patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun 222 (1996) 678-682
12. Matsumori A., Ohashi N., Nishio R., Kakio T., Hara M., Furukawa Y., Ono K., Shioi T., Hasegawa K., and Sasayama S. Apical hypertrophic cardiomyopathy and hepatitis C virus infection. Jpn Circ J 63 (1999) 433-438
13. Matsumori A., Yutani C., Ikeda Y., Kawai S., and Sasayama S. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 80 (2000) 1137-1142
14. Matsumori A., Hara M., Nagai S., Izumi T., Ohashi N., Ono K., and Sasayama S. Hypertrophic cardiomyopathy as a manifestation of cardiac sarcoidosis. Jpn Circ J 64 (2000) 679-683
15. Matsumori A., Furukawa Y., Hasegawa K., Sato Y., Nakagawa H., Morikawa Y., Miura K., Ohno Y., Tamakoshi A., Inaba Y., and Sasayama S. Epidemiologic and clinical characteristics of cardiomyopathies in Japan: results from nationwide surveys. Circ J 66 (2002) 323-336
16. Miura K., Nakagawa H., Morikawa Y., Sasayama S., Matsumori A., Hasegawa K., Ohno Y., Tamakoshi A., Kawamura T., and Inaba Y. Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey. Heart 87 (2002) 126-130
17. Miura K., Matsumori A., Nasermoaddeli A., Soyama Y., Morikawa Y., Sakurai M., Kitabatake A., Nagai M., Inaba Y., and Nakagawa H. Prognosis and prognostic factors in patients with idiopathic dilated cardiomyopathy in Japan. Circ J 72 (2008) 343-348
18. Liu P.P., and Mason J.W. Advances in the understanding of myocarditis. Circulation 104 (2001) 1076-1082
19. Matsumori A., and Kawai C. An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus. Circulation 66 (1982) 355-360
20. Matsumori A., and Kawai C. An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice. Circulation 65 (1982) 1230-1235
21. Matsumori A. Animal models: pathological findings and therapeutic considerations. In: Banatvala J, Edward A, editors. Viral infection of the heart. London; 1993. p. 110-37.
22. Kawano H., Kawai S., Nishijo T., Shirai T., Inagaki Y., and Okada R. An autopsy case of hypertrophic cardiomyopathy with pathological findings suggesting chronic myocarditis. Jpn Heart J 35 (1994) 95-105
23. Matsumori A. Introductory chapter. In: Matsumori A. (Ed). Cardiomyopathies and heart failure. Biomolecular infectious and immune mechanisms (2003), Kluwer Academic Publisher, Boston 1-15
24. Matsumori A., Matoba Y., and Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92 (1995) 2519-2525
25. Matsumori A. Role of hepatitis C virus in myocarditis and cardiomyopathies. J Geriatr Cardiol 1 (2004) 83-89
26. Teragaki M., Nishiguchi S., Takeuchi K., Yoshiyama M., Akioka K., and Yoshikawa J. Prevalence of hepatitis C virus infection among patients with hypertrophic cardiomyopathy. Heart Vessels 18 (2003) 167-170
27. Mason J.W., O'Connell J.B., Herskowitz A., Rose N.R., McManus B.M., Billingham M.E., and Moon T.E. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333 (1995) 269-275
28. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., and Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
29. Matsumori A., Shimada T., Chapman N.M., Tracy S.M., and Mason J.W. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail 12 (2006) 293-298
30. Shichi D., Matsumori A., Naruse T.K., Inoko H., and Kimura A. HLA-DPbeta chain may confer the susceptibility to hepatitis C virus-associated hypertrophic cardiomyopathy. Int J Immunogenet 35 (2008) 37-43
31. Shichi D., Kikkawa E.F., Ota M., Katsuyama Y., Kimura A., Matsumori A., Kulski J.K., Naruse T.K., and Inoko H. The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. Tissue Antigens 66 (2005) 200-208
32. Ooyake N., Kuzuo H., Hirano Y., Shimada T., and Matsumori A. Myocardial injury induced by hepatitis C virus and interferon therapy [Abstract]. J Jpn Soc Int Med 88 suppl. (1999) 241
33. Sato Y., Takatsu Y., Yamada T., Kataoka K., Taniguchi R., Mimura R., Sasayama S., and Matsumori A. Interferon treatment for dilated cardiomyopathy and striated myopathy associated with hepatitis C virus infection based on serial measurements of serum concentrations of cardiac troponin T. Jpn Circ J 64 (2000) 321-324
34. Crabb C. Infectious diseases. Hard-won advances spark excitement about hepatitis C. Science 294 (2001) 506-507
35. Wang L, Li Y, Li T, Zhuang H, Matsumori A. The association of increased concentration of NT-proBNP with hepatitis viruses infection [Abstract]. In: The first international congress of cardiomyopathies and myocarditis. Kyoto, Japan; March 10-13, 2007.
36. Sheikh S. Heart failure in Pakistan. A demographic survey [Abstract]. In: The 10th annual scientific meeting of the Japanese Heart Failure Society. Tokyo, Japan; October 13-15, 2005.
37. Hui J.M., Sud A., Farrell G.C., Bandara P., Byth K., Kench J.G., McCaughan G.W., and George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterol 125 (2003) 1695-1704
38. Matsumori A., Ohashi N., Hasegawa K., Sasayama S., Eto T., Imaizumi T., Izumi T., Kawamura K., Kawana M., Kimura A., Kitabatake A., Matsuzaki M., Nagai R., Tanaka H., Hiroe M., Hori M., Inoko H., Seko Y., Sekiguchi M., Shimotohno K., Sugishita Y., Takeda N., Takihara K., Tanaka M., Yokoyama M., et al. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jpn Circ J 62 (1998) 389-391
39. Ishizaka N., Ishizaka Y., Takahashi E., Tooda E., Hashimoto H., Nagai R., and Yamakado M. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 359 (2002) 133-135
40. Oyake N., Shimada T., Murakami Y., Ishibashi Y., Satoh H., Suzuki K., Matsumory A., and Oda T. Hepatitis C virus infection as a risk factor for increased aortic stiffness and cardiovascular events in dialysis patients. J Nephrol 21 (2008) 345-353